Aquestive Therapeutics (AQST)

Aquestive’s commercial portfolio includes products such as Suboxone, a buprenorphine and naloxone sublingual film used in opioid dependence treatment, along with Emylif, Ondif, and Sympazan. Sympazan is an oral film formulation of clobazam used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome. The company generates most of its revenue in the United States, where it markets or licenses products and collaborates with partners across specialty pharmaceutical channels.

The company’s pipeline is focused on areas where rapid, convenient, or non-invasive administration can be clinically important. Its later-stage central nervous system programs include Libervant, a diazepam buccal film developed for seizure clusters. Aquestive is also advancing AQST-108, an epinephrine product candidate intended for severe allergic reactions, including anaphylaxis. That program reflects the company’s effort to address emergency-use markets traditionally dominated by injectable formats.

AQST gives investors exposure to a small-cap pharmaceutical business built around drug delivery innovation rather than novel molecular discovery alone. Its prospects depend on regulatory approvals, commercial execution, intellectual property protection, manufacturing reliability, reimbursement, and competition from both branded and generic products. The company’s differentiation lies in applying its delivery platform to therapies where ease of use, portability, and speed of administration can influence patient outcomes.